Secular trends in recombinant erythropoietin therapy among the U.S. hemodialysis population: 1990–1996
- 1 January 1998
- journal article
- Published by Elsevier in Kidney International
- Vol. 54 (6) , 2129-2139
- https://doi.org/10.1046/j.1523-1755.1998.00187.x
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- The effect of insurance status on use of recombinant erythropoietin therapy among end-stage renal disease patients in three statesAmerican Journal of Kidney Diseases, 1996
- State of the Art Lecture: The future of r-HuEPONephrology Dialysis Transplantation, 1995
- The Use of Health Care Financing Administration Data for the Development of a Quality Improvement Project on the Treatment of AnemiaAmerican Journal of Kidney Diseases, 1994
- The Relationship of Provider Organizational Status and Erythropoietin Dosing in End Stage Renal Disease PatientsMedical Care, 1994
- Medicare Payment Policy and Recombinant Erythropoietin Prescribing for Dialysis PatientsAmerican Journal of Kidney Diseases, 1993
- Early dosing practices and effectiveness of recombinant human erythropoietinKidney International, 1993
- Investigating Erythropoietin ResistanceNew England Journal of Medicine, 1993
- Effect of Serum Parathyroid Hormone and Bone Marrow Fibrosis on the Response to Erythropoietin in UremiaNew England Journal of Medicine, 1993
- Recombinant Human Erythropoietin in Anemic Patients with End-Stage Renal DiseaseAnnals of Internal Medicine, 1989
- Correction of the Anemia of End-Stage Renal Disease with Recombinant Human ErythropoietinNew England Journal of Medicine, 1987